JUL 24, 2018 01:15 PM PDT

FDA Approves New Drug for Refractory/Relapsed AML

Adults with relapsed or refractory Acute Myeloid Leukemia (AML) have very few options for treatments until this month.  The United States Food and Drug Administration (FDA) approved the first of a new class of cancer drug which is administered in a pill form.  Tibsovo (ivosidenib) will be available for adults either suffering from an AML that has not responded to other therapies or for patients whose AML has returned after having been treated initially with another course of therapy.  Tibsovo is an IDH1 inhibitor, meaning the pill prevents isocitrate dehydrogenase type 1’s (IDH1) neoplastic activity on a molecular biology level. IDH is an enzyme in the citric acid cycle and is found to be mutated in a variety of cancers, according to the literature. 

According to Richard Pazdur, MD, the Director of the Oncology Center of Excellence and Office of Hematology and Oncology Products at the FDA, “Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation.”  The clinical trials involving Tibsovo (also known as AG120) were associated with complete remission for some patients and reduction in required transfusions in other patients. 

This drug was granted an FDA fast track and priority review label as well as an orphan drug description because this affects smaller numbers of patients with this an IDH1 mutation. 

Testing has been developed for IDH1 and IDH2 genes and they are most often analyzed simultaneously; testing can be done on plasma for hematological disease like in this case.  Solid tumors can also be tested.  IDH1 mutations have been found in gliomas, chondrosarcomas, and cholangiocarcinomas, colon and lung cancers, and melanomas.  For some of these cancers, the treatment options and prognosis are poor, so this new drug class presents potential options for them in the future.  The current procedural terminology (CPT) code for this testing was updated in 2018 to include IDH1 (81120) and IDH2 (81121) from a previous Tier 2 molecular pathology code the previous year.  

There are currently clinical trials underway examining the efficacy and safety of IDH inhibitor drugs in the US, France, China, and Germany for gliomas, (NCT02771301, NCT02454634, NCT02597335), myeloid neoplasms beyond AML (NCT03564821), and cholangiocarcinomas (NCT02989857).   

Agios Pharmaceuticals, the producer of Tibsovo, has indicated that this treatment will be very expensive, perhaps topping six figures for the few months patients would be on it.  There are also some side effects discussed in the video linked to this article but were found to be manageable.

Sources: FDA, NCI, ClinicalTrials.Gov, Agios, LabCorp,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 30, 2018
Cell & Molecular Biology
MAY 30, 2018
Diagnosing Deadly Kidney Cancers Sooner
Researchers have found that deadly kidney cancers can be identified by assessing their evolutionary path, which is different for distinct types....
JUN 05, 2018
Cell & Molecular Biology
JUN 05, 2018
Mechanism of Aspirin's Anti-Colon Cancer Effects Revealed
For some people, aspirin can help prevent colon cancer; now researchers have learned more about how that happens....
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 14, 2018
Cancer
AUG 14, 2018
New Drug for Refractory Cutaneous T-cell Lymphoma
Mogamulizumab was approved by the FDA this month after a very successful Phase III clinical trial demonstrating its effectiveness in treating patients with challenging CTCL....
OCT 05, 2018
Cancer
OCT 05, 2018
FDA approves a new drug for an advanced type of skin cancer
As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. A...
OCT 14, 2018
Immunology
OCT 14, 2018
The Stem of Cancer
Scientists reveal a pathway involved in cancer cell ability to act as stem cells...
Loading Comments...